Solvay Pharmaceuticals CEO Dodd joins from Wyeth; Mahady named Wyeth pharmaceuticals president.
SOLVAY PHARMACEUTICALS CEO IS EX-WYETH EXEC DODD, who was named to head Solvay's U.S. Pharmaceuticals business Aug. 17. David Dodd, 45, was previously Wyeth-Ayerst senior VP-pharmaceutical products. He succeeds James Warren, PhD, who left Solvay in March for an academic position. Solvay Senior VP-Sales & Marketing Laurence Downey, MD, had been acting as interim CEO.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth